Pharma IQ Members

Amorphous Solids

Amorphous Solids are solids that have a disordered atomic structure. In contrast, solids that exhibit long-range order in the atomic positions are called crystallines or morphous. Most classes of solid materials can be found or prepared in an amorphous form. For instance, common window glass is an amorphous solid, many polymers (such as polystyrene) are amorphous, and even junk foods such as cotton candy are amorphous solids.

Niamh Madigan

One of the main challenges when working with Amorphous materials is being able to predict and characterise properties which are common to crystalline products. Yaroslav Khimyak, Professor in NMR at the University of East Anglia in the UK explains...

Contributor: Niamh Madigan
09/02/2012 08:00:00 PM EDT
Pharma IQ Surveys

In preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions and will take less than 3 minutes to complete...

Contributor: Pharma IQ Surveys
04/26/2012 08:00:00 PM EDT
Marc Descamps

Marc Descamps, Professor in Solid State Physics at Université Lille and Lead of the European ID Network for Improved Drug Efficacy and Availability, joins Pharma IQ to discuss the use of amorphous pharmaceutical materials to improve necessary...

Contributor: Marc Descamps
08/18/2011 08:00:00 PM EDT
Ensuring Stability the Biggest Amorphous Challenge for 88.2% of Developers

The use of amorphous pharmaceutical materials is widely considered an effective way of improving favourable drug properties and the latest findings from Pharma IQ suggest that many developers consider them an essential resource. But as Marc...

Contributor: Pharma IQ
07/27/2011 08:00:00 PM EDT
Helen Winsor

Marc Descamps, Professor in Solid State Physics at Université Lille and Lead of the European ID Network for Improved Drug Efficacy and Availability, joins Helen Winsor from Pharma IQ, to discuss the use of amorphous pharmaceutical materials to...

Contributor: Helen Winsor
05/31/2011 08:00:00 PM EDT
Stephanie Greco

Stéphanie Greco, Analyst Scientist, Pharmaceutical Science Department, Sanofi-aventis, joined Pharma IQ to discuss predicting physical stability of amorphous solid dispersions. Pharma IQ: Please could you tell us about your previous achievements...

Contributor: Stephanie Greco
05/22/2011 08:00:00 PM EDT
Amber Scorah

Amorphous spray dried dispersions (SDDs) have emerged as a broadly applicable technology for the delivery of poorly soluble drug molecules. Methods for formulating and predicting the physical stability of these formulations are becoming better...

Contributor: Amber Scorah
03/09/2011 07:00:00 PM EST
Investing in Techniques for Developing Amorphous Materials

The use of amorphous materials presents many opportunities for the pharmaceutical industry in terms of increased solubility and bioavailability, particularly as a growing number of insoluble active pharmaceutical ingredients (APIs) are developed...

Contributor: Pharma IQ
02/13/2011 07:00:00 PM EST
Helen Winsor

Amorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development. Dr. Dave Miller, Senior Principal Scientist at Hoffmann-La Roche, speaks to Helen Winsor from Pharma IQ, about the...

Contributor: Helen Winsor
09/05/2010 08:00:00 PM EDT
Pharma IQ News

There has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities.  IQPC’s Polymorphism & Crystallization Scientific Forum, taking...

Contributor: Pharma IQ News
08/23/2010 08:00:00 PM EDT
Pharma IQ

Dr. Dave Miller, Senior Principal Scientist at Hoffmann La Roche, shares his views on how to optimise amorphous form selection, techniques to enhance amorphous drug performance and the best strategies to stabilise amorphous forms. He also offers...

Contributor: Pharma IQ
07/11/2010 08:00:00 PM EDT
Be Prepared for Scale Up of Co-crystal Production

Dr. Vaibhav Sihorkar, Head of Pharmaceutical Development at Aurigene Discovery Technologies in India, gave Pharma IQ his insights on existing challenges to co-crystal commercialisation.What is the major challenge in achieving scale up of co-...

Contributor: Vaibhav Sihorkar
07/07/2010 08:00:00 PM EDT
Pharma IQ

The perfect ingredients and compounds help to make many drugs effective, but the very best medicines developed by the pharmaceutical sector are also formulated to react in the most suitable way once inside the human body. Issues such as...

Contributor: Pharma IQ
06/17/2010 08:00:00 PM EDT
Pharma IQ

The amorphous state is inherently instable. How do we keep amorphous forms from crystallising for as long as possible? Dr. Joseph Lubach from Genentech, joined Pharma IQ to discuss the challenges of physical and chemical stability, as well as...

Contributor: Pharma IQ
06/13/2010 08:00:00 PM EDT